Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 15, 2026 at 11:00 a.m. Eastern. Investors will elect nine common directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify RSM US LLP as independent auditor for 2026.
As of April 23, 2026, 128,674,548 shares of Common Stock and 130,000 shares of Convertible Preferred Stock, convertible into 38,470,359 Common shares, were entitled to vote together. Preferred holders can elect one board member while they hold at least 5% of the as-converted Common. Executive pay blends base salary, annual cash bonuses tied mainly to net revenue and Adjusted EBITDA, and long-term equity including stock options, RSUs and new performance share awards, which in 2025 vested at the maximum level for the first tranche based on revenue growth.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow exercised stock options to acquire 958 shares of Class A Common Stock on January 10, 2025 at $1.24 per share. The option was fully vested and, after the transaction, he directly holds 900,682 shares.
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at a price of $2.681 per share on March 9, 2026. Following this transaction, his directly held stake increased to 291,014 shares.
Organogenesis Holdings Inc. director Michael Joseph Driscoll bought 10,000 shares of Class A Common Stock in an open-market purchase. He paid about $2.67 per share, for a total of roughly $26,688. Following this transaction, he directly owns 225,707 shares, making this a relatively small addition to his stake.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported a tax-related share transfer. On this transaction, 700 shares of Class A common stock were disposed of at $3.21 per share to cover tax withholding obligations, leaving him with 275,524 directly held shares.
Organogenesis Holdings Inc. executive Antonio S. Montecalvo reported updated stock transactions related to an equity award. The amended filing corrects the number of Class A Common shares acquired upon vesting of a performance share award and the shares withheld to cover taxes. On February 18, 2026, he was granted 11,330 shares at a price of $0.00 per share and had 3,778 shares withheld at $3.84 per share to satisfy tax obligations. After these adjustments, he directly holds 226,238 Class A Common shares. The amendment states no other changes were made to the original report.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity. On February 18, 2026, he acquired 188,856 shares of Class A common stock as a grant or award at $0.00 per share, and disposed of 91,311 shares at $3.84 per share to cover tax obligations. The amendment corrects the numbers previously reported for the performance share vesting and related tax-withholding, with no other changes to the original Form 4.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow filed an amended insider transaction report. On February 18, 2026, he acquired 48,818 shares of Class A common stock at $0.00 per share through the vesting and settlement of a performance share award, and 11,887 shares were disposed of at $3.84 per share to cover tax obligations. After these adjustments, he directly owns 899,724 shares. The amendment corrects the previously reported share amounts related to this award, with no other changes.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares reported from a performance share award that vested on February 18, 2026 and the related tax withholding. The filing now shows an award acquisition of 49,102 shares at a stated price of $0.00 per share and a tax-withholding disposition of 16,375 shares at $3.84 per share. Following these adjustments, Bilbo directly holds 1,128,312 shares of Class A Common Stock.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported amended equity award details. On February 18, 2026, he acquired 44,040 shares of Class A common stock as a grant at no cost, and 14,687 shares were withheld at $3.84 per share to cover tax obligations. This amendment only corrects the share counts previously reported for the award vesting and related tax withholding.